Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus FERRIC CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus FERRIC CITRATE.
AURYXIA vs FERRIC CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Category C
Category C
Phosphate Binder
Phosphate Binder